Actions of octocoral and tobacco cembranoids on nicotinic receptors


Autoria(s): FERCHMIN, P. A.; PAGAN, One R.; ULRICH, Henning; SZETO, Ada C.; HANN, Richard M.; ETEROVIC, Vesna A.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2009

Resumo

Nicotinic acetylcholine receptors (AChRs) are pentameric proteins that form agonist-gated cation channels through the plasma membrane. AChR agonists and antagonists are potential candidates for the treatment of neurodegenerative diseases. Cembranoids are naturally occurring diterpenoids that contain a 14-carbon ring. These diterpenoids interact with AChRs in complex ways: as irreversible inhibitors at the agonist sites, as noncompetitive inhibitors, or as positive modulators, but no cembranoid was ever shown to have agonistic activity on AChRs. The cembranoid eupalmerin acetate displays positive modulation of agonist-induced currents in the muscle-type AChR and in the related gamma-aminobutyric acid (GABA) type A receptor. Moreover, cembranoids display important biological effects, many of them mediated by nicotinic receptors. Cembranoids from tobacco are neuroprotective through a nicotinic anti-apoptotic mechanism preventing excitotoxic neuronal death which in part could result from anti-inflammatory properties of cembranoids. Moreover, tobacco cembranoids also have anti-inflammatory properties which could enhance their neuroprotective properties. Cembranoids from tobacco affect nicotine-related behavior: they increase the transient initial ataxia caused by first nicotine injection into naive rats and inhibit the expression of locomotor sensitization to repeated injections of nicotine. In addition, cembranoids are known to act as anti-tumor compounds. In conclusion, cembranoids provide a promising source of lead drugs for many clinical areas, including neuroprotection, smoking-cessation, and anti-cancer therapies. (C) 2009 Elsevier Ltd. All rights reserved.

National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)/NCRR/SNRP[NS39408]

National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)/NCRR/SNRP

NIH/NIGMS/MBRS[2 S06 GM050695]

NIH/NIGMS/MBRS

NIH/NCRR/INBRE[P20RR16470]

NIH/NCRR/INBRE

NIH/RCMI

NIH/RCMI[G12 RR03035]

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)[06/61285-9]

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq)

Identificador

TOXICON, v.54, n.8, p.1174-1182, 2009

0041-0101

http://producao.usp.br/handle/BDPI/31000

10.1016/j.toxicon.2009.02.033

http://dx.doi.org/10.1016/j.toxicon.2009.02.033

Idioma(s)

eng

Publicador

PERGAMON-ELSEVIER SCIENCE LTD

Relação

Toxicon

Direitos

restrictedAccess

Copyright PERGAMON-ELSEVIER SCIENCE LTD

Palavras-Chave #Cembranoid #Neuroprotection #Apoptosis #Soft coral #Tobacco #ACUTE HIPPOCAMPAL SLICES #MARINE NATURAL-PRODUCT #LIGAND-BINDING DOMAIN #ACUTE ISCHEMIC-STROKE #ACETYLCHOLINE-RECEPTOR #AGONIST SITES #NONCOMPETITIVE INHIBITORS #IRREVERSIBLE INHIBITORS #ALPHA-BUNGAROTOXIN #LOCOMOTOR-ACTIVITY #Pharmacology & Pharmacy #Toxicology
Tipo

article

original article

publishedVersion